Related Experiment Video
Updated: Aug 24, 2026
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery
Shiuh-Lin Hwang1, Chih-Lung Lin, Chi-Yun Cheng
1Division of Neurosurgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Abstract:
The suppression of immune responses in malignant gliomas is thought to be involved in glioma pathogenesis. The newly identified tumor-secreted soluble decoy receptor 3 (DcR3) can bind to the ligands CD95L and LIGHT, thereby neutralizing their pro-apoptotic actions. Little is known of the production of DcR3 by glioma cells. This study investigated the serum concentration of DcR3 in glioma patients before and after tumor removal. Blood samples were taken from 17 glioma patients and 10 control patients. The serum DcR3 concentration was measured using a DcR3 enzyme-linked immunosorbent assay. There was no statistically significant difference between preoperative (0.069 +/- 0.027 ng/mL) and postoperative DcR3 concentrations (0.068 +/- 0.022 ng/mL; p = 0.951). Similarly, there was no difference in preoperative DcR3 concentration between glioma patients (0.069 +/- 0.027 ng/mL) and controls (0.063 +/- 0.023 ng/mL; p = 0.106). Our study demonstrated no alteration in DcR3 concentration in glioma patients before and after tumor removal.
Insights
Serum levels of decoy receptor 3 (DcR3) do not change significantly in malignant glioma patients after tumor removal. This study found no difference in DcR3 concentration before or after surgery, or compared to healthy controls.
Area of Science:
- Neuro-oncology
- Immunology
- Molecular Biology
Background:
- Malignant gliomas exhibit immune suppression, potentially involving tumor-secreted factors.
- Soluble decoy receptor 3 (DcR3) is a newly identified protein that neutralizes pro-apoptotic ligands like CD95L and LIGHT.
- The production and role of DcR3 in glioma pathogenesis are not well understood.
Purpose of the Study:
- To investigate the serum concentration of decoy receptor 3 (DcR3) in patients with malignant glioma.
- To compare DcR3 levels before and after surgical tumor removal.
- To assess differences in DcR3 concentration between glioma patients and healthy controls.
Main Methods:
- Serum samples were collected from 17 glioma patients and 10 control individuals.
- DcR3 concentrations were quantified using a DcR3 enzyme-linked immunosorbent assay (ELISA).
- Statistical analysis was performed to compare preoperative and postoperative DcR3 levels, and between patient and control groups.
Main Results:
- No statistically significant difference was observed in serum DcR3 concentrations between preoperative (0.069 +/- 0.027 ng/mL) and postoperative (0.068 +/- 0.022 ng/mL) samples (p = 0.951).
- Preoperative DcR3 concentrations in glioma patients (0.069 +/- 0.027 ng/mL) were not significantly different from those in control subjects (0.063 +/- 0.023 ng/mL) (p = 0.106).
Conclusions:
- Serum decoy receptor 3 (DcR3) levels do not appear to be altered in malignant glioma patients.
- Tumor removal does not significantly impact serum DcR3 concentrations.
- Further research is needed to elucidate the role of DcR3 in glioma, as serum levels do not correlate with tumor burden in this study.
